Ontario HIV Treatment Network   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Toronto Canada (1998)

Organization Overview

First Clinical Trial
2002
NCT00202228
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Ontario HIV Treatment Network

Active Ingredients

Drugs in Phase 4 Trials (4)

levocarnitine (carnitor) (1 trial)

riboflavin (1 trial)

rosuvastatin (crestor) (1 trial)

thiamine (1 trial)

Drugs in Phase 3 Trials (2)

citalopram (celexa) (1 trial)

inactivated influenza vaccine (1 trial)

Drugs in Phase 2 Trials (3)

alvac-hiv vaccine (1 trial)

omega-3 fatty acids (Omacor) (1 trial)

vitamin e (1 trial)

Drugs in Other Trials (1)

multivitamins (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acidosis (Phase 4)

Acidosis, Lactic (Phase 4)

Acquired Immunodeficiency Syndrome (Phase 4)

Cardiovascular Diseases (Phase 4)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Fatty Liver (Phase 2)

Hepatitis (Phase 3)

Hepatitis C (Phase 3)

HIV Infections (Phase 4)

Immunologic Deficiency Syndromes (Phase 4)

Influenza, Human (Phase 3)

Lipodystrophy (Phase 4)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 10